IL6 and COVID-19: Elevated levels of IL-6 correlate with morbidity and mortality in COVID-19 patients [8] and the antibody tocilizumab, which targets IL-6, improved survival in hospitalized COVID-19 patients with a demand for oxygen therapy and systemic inflammation.